Apotex announced that Health Canada has approved CLOBIVIS (clobetasol propionate ophthalmic suspension, 0.05%), indicated for the treatment of postoperative inflammation and pain following cataract surgery.[1]
Licensed from Formosa, CLOBIVIS is formulated using nanoparticle technology to deliver a uniform, ophthalmic suspension. Its approval marks a meaningful enhancement to Apotex’s growing ophthalmology portfolio and reinforces the Company’s commitment to expanding access to treatment options for Canadian patients.
“As a Force for Health, Apotex seeks to ensure patients have access to innovative treatments,” said Martin Arès, President, Apotex Canada and Rest of World (ROW). “The approval of CLOBIVIS is another milestone in broadening the availability of ophthalmology medicines through strategic partnerships that support ophthalmic care for Canadians, and it reflects our Journey of Health Strategy to expand access to new therapies.”
Healthcare professionals should refer to the complete Product Monograph for detailed information on warnings, precautions, adverse reactions, and patient monitoring requirements.
Learn more at www.apotex.com.
[1] Product Monograph: https://pdf.hres.ca/dpd_pm/00083880.PDF
